SELLAS Life Sciences GroupSLS +1.10%25 Market Cap is $1,802.14 Mil as of Jun. 25, 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, SELLAS Life Sciences Group ranks better than 86.93% on this metric.
SELLAS Life Sciences Group's quarterly market cap
increased
from Sep. 2025 ($201.38 Mil) to Dec. 2025 ($577.20 Mil) and
increased
from Dec. 2025 ($577.20 Mil) to Mar. 2026 ($767.04 Mil).
SELLAS Life Sciences Group's annual market cap
increased
from Dec. 2023 ($34.06 Mil) to Dec. 2024 ($76.94 Mil) and
increased
from Dec. 2024 ($76.94 Mil) to Dec. 2025 ($577.20 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SELLAS Life Sciences Group's Enterprise Value for Today is $1,695.91 Mil.
SELLAS Life Sciences Group (NAS:SLS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SELLAS Life Sciences Group Market Cap Related Terms
SELLAS Life Sciences Group Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SELLAS Life Sciences Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Market Cap distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group (SLS) has a Market Cap of $1,802.14 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #187 out of 1431 companies in the Biotechnology industry, placing it in the top 13.1%.
Is SELLAS Life Sciences Group's Market Cap too high?
SELLAS Life Sciences Group's current Market Cap is $1,802.14 Mil. The Biotechnology industry median Market Cap is 117.63. SELLAS Life Sciences Group's value of $1,802.14 Mil is 1432.1% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #187 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Market Cap compare to SNDX and CAPR?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #187 out of 1431 companies for Market Cap. This places SELLAS Life Sciences Group in the top 13% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. SELLAS Life Sciences Group's value of $1,802.14 Mil is 1432.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Market Cap of $1,802.14 Mil is 1432.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Market Cap is $1,802.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Market Cap of $1,802.14 Mil. The current Market Cap is $1,802.14 Mil and 1432.1% above the Biotechnology industry median of 117.63. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Market Cap is $1,802.14 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score
Get the complete analysis for SLS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
